Page 813 - Williams Hematology ( PDFDrive )

788 Part VI: The Erythrocyte <CN>: <CT> PB

375. Ruggeri A, Eapen M, Scaravadou A, et al: Umbilical cord blood transplantation for 399. Itano HA, Neel JV: A new inherited abnormality of human hemoglobin. Proc Natl Acad
children with thalassemia and sickle cell disease. Biol Blood Marrow Transplant Sci U S A 36(11):613–617, 1950.
17(9):1375–1382, 2011. 400. Spaet TH, Alway RH, Ward G: Homozygous type c hemoglobin. Pediatrics 12(5):483–
376. Bolanos-Meade J, Fuchs EJ, Luznik L, et al: HLA-haploidentical bone marrow trans- 490, 1953.
plantation with posttransplant cyclophosphamide expands the donor pool for patients 401. Ranney HM, Larson DL, McCormack GH Jr: Some clinical, biochemical and genetic
with sickle cell disease. Blood 120(22):4285–4291, 2012. observations on hemoglobin C. J Clin Invest 32(12):1277–1284, 1953.
377. Smith-Whitley K, Thompson AA: Indications and complications of transfusions in 402. Nagel RL, Steinberg MH: Hb SC disease and Hb C disorders, in Disorders of Hemo-
sickle cell disease. Pediatr Blood Cancer 59(2):358–364, 2012. globin: Genetics, Pathophysiology, and Clinical Management, edited by Steinberg MH,
378. Telen MJ: Principles and problems of transfusion in sickle cell disease. Semin Hematol Forget BG, Higgs DR, Nagel RL, pp 756–785. Cambridge University Press, Cambridge,
38(4):315–323, 2001. 2001..
379. Chien S, Usami S, Bertles JF: Abnormal rheology of oxygenated blood in sickle cell 403. Boehm CD, Dowling CE, Antonarakis SE, et al: Evidence supporting a single origin of
anemia. J Clin Invest 49(4):623–634, 1970. the beta(C)-globin gene in blacks. Am J Hum Genet 37(4):771–777, 1985.
380. Morris CL, Gruppo RA, Shukla R, et al: Influence of plasma and red cell factors on the 404. Cook CM, Smeltzer MP, Mortier NA, et al: The clinical and laboratory spectrum of Hb
rheologic properties of oxygenated sickle blood during clinical steady state. J Lab Clin C [beta6(A3)Glu—>Lys, GAG>AAG] disease. Hemoglobin 37(1):16–25, 2013.
Med 118(4):332–342, 1991. 405. Itano HA, Bergren WR, Sturgeon P: Identification of fourth abnormal human hemoglo-
381. Schmalzer EA, Lee JO, Brown AK, et al: Viscosity of mixtures of sickle and normal red bin. J Am Chem Soc 76:2278, 1954.
cells at varying hematocrit levels. Implications for transfusion. Transfusion 27(3):228– 406. Fucharoen S: Hb E disorders, in Disorders of Hemoglobin: Genetics, Pathophysiology,
233, 1987. and Clinical Management, edited by Steinberg MH, Forget BG, Higgs DR, Nagel RL, pp
382. Vichinsky EP: Current issues with blood transfusions in sickle cell disease. Semin 1139–1154. Cambridge University Press, Cambridge, 2001.
Hematol 38(1 Suppl 1):14–22, 2001. 407. Atichartakarn V, Chuncharunee S, Archararit N, et al: Intravascular hemolysis, vascular
383. Rosse WF, Gallagher D, Kinney TR, et al: Transfusion and alloimmunization in sickle endothelial cell activation and thrombophilia in splenectomized patients with hemo-
cell disease. The Cooperative Study of Sickle Cell Disease. Blood 76(7):1431–1437, 1990. globin E/beta-thalassemia disease. Acta Haematol 132(1):100–107, 2014.
384. Yazdanbakhsh K, Ware RE and Noizat-Pirenne F. Red blood cell alloimmunization in 408. Fucharoen S, Siritanaratkul N, Winichagoon P, et al: Hydroxyurea increases hemoglo-
sickle cell disease: Pathophysiology, risk factors, and transfusion management. Blood bin F levels and improves the effectiveness of erythropoiesis in beta-thalassemia/hemo-
120(3):528–537, 2012. globin E disease. Blood 87(3):887–892, 1996.
385. Wahl S, Quirolo KC: Current issues in blood transfusion for sickle cell disease. Curr 409. Itano HA: A third abnormal hemoglobin associated with hereditary hemolytic anemia.
Opin Pediatr 21(1):15–21, 2009. Proc Natl Acad Sci U S A 37(12):775–784, 1951.
386. Talano JA, Hillery CA, Gottschall JL, et al: Delayed hemolytic transfusion reaction/ 410. Huisman THJ, Carver MFH, Efremov GD: A Syllabus of Human Hemoglobin Variants.
hyperhemolysis syndrome in children with sickle cell disease. Pediatrics 111(6 Pt The Sickle Cell Anemia Foundation, Augusta, GA, 1998.
1):e661–e665, 2003. 411. Cathie IAB: Apparent idiopathic Heinz body anaemia. Great Ormond St J 3:343, 1952.
387. Ballas SK: Iron overload is a determinant of morbidity and mortality in adult patients 412. Wun T, Styles L, DeCastro L, et al: Phase 1 study of the E-selectin inhibitor GMI 1070
with sickle cell disease. Semin Hematol 38(1 Suppl 1):30–36, 2001. in patients with sickle cell anemia. PLoS One 9(7):e101301, 2014.
388. Vichinsky E, Butensky E, Fung E, et al: Comparison of organ dysfunction in transfused 413. Nathan DG, Field J, Lin G, et al: Sickle cell disease (SCD), iNKT cells, and regadenoson
patients with SCD or beta thalassemia. Am J Hematol 80(1):70–74, 2005. infusion. Trans Am Clin Climatol Assoc 123:312–317; discussion 317–318, 2012.
389. Fung EB, Harmatz P, Milet M, et al: Morbidity and mortality in chronically transfused 414. Field JJ, Lin G, Okam MM, et al: Sickle cell vaso-occlusion causes activation of iNKT
subjects with thalassemia and sickle cell disease: A report from the multi-center study cells that is decreased by the adenosine A2A receptor agonist regadenoson. Blood
of iron overload. Am J Hematol 82(4):255–265, 2007. 121(17):3329–3334, 2013.
390. Brittenham GM, Cohen AR, McLaren CE, et al: Hepatic iron stores and plasma ferritin 415. Daak AA, Ghebremeskel K, Hassan Z, et al: Effect of omega-3 (n-3) fatty acid supple-
concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol mentation in patients with sickle cell anemia: Randomized, double-blind, placebo-con-
42(1):81–85, 1993. trolled trial. Am J Clin Nutr 97(1):37–44, 2013.
391. National Institutes of Health, Division of Blood Diseases and Resources: The Manage- 416. Morris CR, Kuypers FA, Lavrisha L, et al: A randomized, placebo-controlled trial of
ment of Sickle Cell Disease, ed 4. NIH Publication No. 02–2117. NIH, Bethesda, MD, arginine therapy for the treatment of children with sickle cell disease hospitalized with
2002. Available at: http://www.nhlbi.nih.gov/health/prof/blood/sickle/sc_mngt.pdf vaso-occlusive pain episodes. Haematologica 98(9):1375–1382, 2013.
392. Silliman CC, Peterson VM, Mellman DL, et al: Iron chelation by deferoxamine in sickle 417. Goldman RD, Mounstephen W, Kirby-Allen M, et al: Intravenous magnesium sulfate
cell patients with severe transfusion-induced hemosiderosis: A randomized, dou- for vaso-occlusive episodes in sickle cell disease. Pediatrics 132(6):e1634–e1641, 2013.
ble-blind study of the dose-response relationship. J Lab Clin Med 122(1):48–54, 1993. 418. Wun T, Soulieres D, Frelinger AL, et al: A double-blind, randomized, multicenter phase
393. Vichinsky E, Onyekwere O, Porter J, et al: A randomised comparison of deferasirox ver- 2 study of prasugrel versus placebo in adult patients with sickle cell disease. J Hematol
sus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Oncol 6:17, 2013.
Br J Haematol 136(3):501–508, 2007. 419. Desai PC, Brittain JE, Jones SK, et al: A pilot study of eptifibatide for treatment of acute
394. Lucania G, Vitrano A, Filosa A, et al: Chelation treatment in sickle-cell-anaemia: Much pain episodes in sickle cell disease. Thromb Res 132(3):341–345, 2013.
ado about nothing? Br J Haematol 154(5):545–555, 2011. 420. Ataga KI, Reid M, Ballas SK, et al: Improvements in haemolysis and indicators of ery-
395. Brittenham GM: Iron-chelating therapy for transfusional iron overload. N Engl J Med throcyte survival do not correlate with acute vaso-occlusive crises in patients with
364(2):146–156, 2011. sickle cell disease: A phase III randomized, placebo-controlled, double-blind study
396. Steinberg MH, Adams JG 3rd, Dreiling BJ: Alpha thalassaemia in adults with sickle-cell of the Gardos channel blocker senicapoc (ICA-17043). Br J Haematol 153(1):92–104,
trait. Br J Haematol 30(1):31–37, 1975. 2011.
397. Wong SC, Ali MA, Boyadjian SE: Sickle cell traits in Canada. Trimodal distribution of 421. Orringer EP, Casella JF, Ataga KI, et al: Purified poloxamer 188 for treatment of
Hb S as a result of interaction with alpha-thalassaemia gene. Acta Haematol 65(3):157– acute vaso-occlusive crisis of sickle cell disease: A randomized controlled trial. JAMA
163, 1981. 286(17):2099–2106, 2001.
398. Sciarratta GV, Sansone G, Ivaldi G, et al: Alternate organization of alpha G-Philadel- 422. Kutlar A, Ataga KI, McMahon L, et al: A potent oral P-selectin blocking agent improves
phia globin genes among U.S. black and Italian Caucasian heterozygotes. Hemoglobin microcirculatory blood flow and a marker of endothelial cell injury in patients with
8(6):537–547, 1984. sickle cell disease. Am J Hematol 87(5):536–539, 2012.

Kaushansky_chapter 49_p0759-0788.indd 788 9/18/15 3:02 PM